Mifepristone
Brand name: Korlym
Rank #184 of 500 drugs by total cost
$83.3M
Total Cost
2,397
Total Claims
$83.3M
Total Cost
108
Prescribers
$35K
Cost per Claim
55
Beneficiaries
2,398
30-Day Fills
$771K
Avg Cost/Provider
22
Avg Claims/Provider
About Mifepristone
Mifepristone (sold as Korlym) was prescribed 2,397 times by 108 Medicare Part D providers in 2023, costing the program $83.3M. At $35K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 181 | Imatinib Mesylate (Imatinib Mesylate) | $85.0M | 40,908 |
| 182 | Clopidogrel Bisulfate (Clopidogrel) | $84.7M | 5,428,304 |
| 183 | Famotidine (Famotidine) | $84.3M | 5,257,365 |
| 184 | Mifepristone (Korlym) | $83.3M | 2,397 |
| 185 | Insulin Nph Hum/Reg Insulin Hm (Humulin 70-30) | $82.3M | 177,501 |
| 186 | Montelukast Sodium (Montelukast Sodium) | $81.3M | 5,086,706 |
| 187 | Certolizumab Pegol (Cimzia) | $79.9M | 11,784 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology